Steven F. Casey, a partner in the firm's Business & Commercial Litigation Practice Group in the Birmingham office, was quoted in a Law360 article, “NJ Reglan Ruling Widens Generic Label Preemption Split,” discussing the recent New Jersey Supreme Court ruling that state law claims alleging generic-drug manufacturers did not adequately warn of neurological risks for Reglan are not preempted by federal law. Mr. Casey states, “I think the courts are troubled by the fact that people who take generics have really no remedy if they experience these serious side effects after Mensing.” Please click here to read the full article.